drugset / Trial / NCT07017036
Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The study duration for individual patients will be up to 55 weeks for the 4-weekly and 3- weekly schedule of the treatment which includes 3 weeks for screening, 48 weeks for Study Medication administration and 4 weeks for follow-up assessments
Timeline
- Start
- 2025-07-01
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Immuglo | Unknown | 200 mg/kg | — |
| Comparator | Immuglo | Unknown | 800 mg/kg | — |
| Subject | V-IMMUNE | Protein / enzyme biologic | 200 mg/kg | — |
| Subject | V-IMMUNE | Protein / enzyme biologic | 800 mg/kg | — |